Septerna, Inc. (NASDAQ:SEPN - Get Free Report) reached a new 52-week low during mid-day trading on Saturday . The stock traded as low as $17.71 and last traded at $17.99, with a volume of 207078 shares trading hands. The stock had previously closed at $20.85.
Analyst Upgrades and Downgrades
SEPN has been the topic of several analyst reports. TD Cowen initiated coverage on Septerna in a report on Tuesday, November 19th. They issued a "buy" rating on the stock. Wells Fargo & Company began coverage on Septerna in a research note on Tuesday, November 19th. They issued an "overweight" rating and a $43.00 price target on the stock. JPMorgan Chase & Co. assumed coverage on Septerna in a research note on Tuesday, November 19th. They set an "overweight" rating and a $38.00 price objective for the company. Finally, Cantor Fitzgerald assumed coverage on shares of Septerna in a report on Tuesday, November 19th. They issued an "overweight" rating and a $50.00 target price on the stock.
Get Our Latest Stock Analysis on Septerna
Septerna Stock Down 13.7 %
The stock's fifty day moving average price is $23.63.
Insider Buying and Selling
In other news, major shareholder Rock Ventures V. L.P. Third bought 370,500 shares of the stock in a transaction dated Monday, October 28th. The stock was bought at an average price of $18.00 per share, for a total transaction of $6,669,000.00. Following the purchase, the insider now directly owns 6,215,591 shares in the company, valued at $111,880,638. This trade represents a 6.34 % increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
Septerna Company Profile
(
Get Free Report)
We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.
Featured Articles
Before you consider Septerna, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Septerna wasn't on the list.
While Septerna currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
